Back to News & Events

Serological Biomarkers of the Extracellular Matrix Reflecting Fibroblast Activity and Endothelial Damage are Elevated in Patients at Risk of MASH With Significant Liver Stiffness

Share this

A co-authored poster by ProSciento and Nordic Bioscience was presented at the SLD EASL Summit by Diana Julie Leeming, mMBA, MSc, PhD, Senior Director, Hepatic & Pulmonary Research at Nordic Bioscience. The poster explores non-invasive biomarkers for hepatic fibrosis in patients at risk of metabolic dysfunction-associated steatohepatitis (MASH).

MASH-related fibrosis results from excessive collagen deposition, increasing liver stiffness. Our research investigates how PRO-C3, PRO-C4, and PRO-C6 biomarkers—which assess fibroblast activation and endothelial damage—correlate with liver stiffness in patients at risk due to obesity and type 2 diabetes.

View abstract at the link to the Abstract Book below, page 133.

Your development journey
starts with a conversation.

ProSciento
Privacy Overview

More information about our Privacy Policy can be found here.